Groups
Company Size (Fulltime employees)
Partnering Objectives
Functionality
Headquartner in China
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Medtech Category
Medtech Development Stage
Index
Countries
Reset

Mr. Adil Saghir India

MedTravo is an online Global Medical Tourism marketplace for an International Medical Travelers Globally which connects patients to the Right Healthcare Providers and Doctors in India, UAE and other 8 South Asian countries in the world. We have helped 2000 patients till date through us who have been to different destinations for their Medical Treatment/ Surgery.

Website:
https://www.medtravo.com
Company Size (Fulltime employees)
11-50
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
I am looking forward to partnered with VC firm/ Family Offices/ High Net Worth Individuals who can invest in the Global Medical Tourism sector.
Headquartner in China
No
Biotech/Pharma Category
Medtech Category
Slides Deck
(pdf, 5.11MB)
MedTravo
Chief Executive Officer 
Functionality
Management

Fernando Salles China

We are a clinical stage biopharma company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders
Website:
http://www.i-mabbiopharma.com/en/
Company Size (Fulltime employees)
201-500
Year of foundation
2016
Partnering Objectives
Please specify your partnering goal
Looking for appropriate opportunities to in-license
Headquartner in China
Yes
Biotech/Pharma Category
I-Mab Biopharma
SVP, Head of US and EU Business Development 
Functionality
Business Development

Mrs. Diana Saraceni Italy

Panakes Partners is a Venture Capital investor financing early and late stage medical companies, with innovative products and great ambition teams.
Panakes invests in seed to pre-IPO rounds mainly in European companies but also in Israel and in the US.
The team provides more than capital working together with entrepreneurs to develop successful businesses as an active and well-connected investor. Panakes has a strong relationships with selected industrial partners of the sector to help companies to accelerate their development
Website:
www.panakes.it
Company Size (Fulltime employees)
1-10
Year of foundation
2015
Partnering Objectives
Please specify your partnering goal
to see companies
Headquartner in China
No
Medtech Category
Panakes Partners SGRSpa
Partner 

Dr. MIke Schopperle United States

CureMeta is a therapeutic oncology biotech with the mission to develop therapeutic antibodies to novel cancer targets that are present in aggressive cancers and to develop new powerful cancer drugs to provide meaningful treatments and cures for patients with metastatic cancer.

We are seeking partners to out-license our lead therapeutic: CM-09, a first in class Antibody-Drug-Conjuate for gastric cancers.

Website:
CureMeta.com
Company Size (Fulltime employees)
1-10
Year of foundation
2012
Partnering Objectives
Headquartner in China
No
Biotech/Pharma Category
Assets Information 1
CM-09, a first-in-class Antibody-Drug-Conjugate for gastric and pancreatic cancers. US patent awarded, patent filed in China, Japan, South Korea, Russian, Australia, India, Brazil and Europe.
Slides Deck
(pdf, 2.95MB)
CureMeta
CSO 

Mrs. Christine Schwenk Germany

TissUse is a Berlin, Germany-based, vibrant growth company who has developed a unique "Multi-Organ-Chip" platform that provides unprecdented preclinical insight on the systemic level using human tissue. This enabling technology platform consists of a miniaturized construct that closely simulates the activity of multiple human organs in their true physiological context. TissUse's Multi-Organ-Chips provide a completely new approach to predict, for example, toxicity, ADME profiles and efficacy in vitro, reducing and replacing laboratory animal testing and streamlining human clinical trials.
TissUse is additionally applying its platform and know-how to develop spin-off programs in a variety of tissue and organ repair areas starting with the cosmetic market of hair transplants.
Website:
https://www.tissuse.com/en/
Company Size (Fulltime employees)
11-50
Year of foundation
2010
Partnering Objectives
Please specify your partnering goal
Introduce TissUse HUMIMIC Multi-Organ-Chip technology & Initiate collaborations
Headquartner in China
No
Your Research Tool and Service name
HUMIMIC Multi-Organ-Chips, Neopapillae Hair Restoration, Technology Transfer, Multi-Organ-Chip Assay Development
Service Description
Multi-Organ-Chip A dynamic Multi-Organ-Chip platform has been designed to allow for easy integration of several organ-equivalents for advanced toxicity testing and cutting-edge disease modelling. Features: • Efficient human-like tissue nutrition • Flexible combination of different tissues • Long-term performance • Physiological shear stress applicable Rapid prototyping for specific customer needs in organ arrangement Neopapillae for Hair Restoration Hair transplantation is a procedure that is currently invasive and costly. TissUse has discovered a more efficient and less painful process. By isolating cells from the dermal papilla, the root of the hair follicle, it is possible to expand and culture those cells to form neopapillae. Each of these neopapilla has the potential to form a brand new hair follicle. Features: • more efficient compared to standard procedures • faster, more convenient and less painful • requires exceptional few biopsies and yields large number of hair inducing transplants Services: Technology Transfer and Multi-Organ-Chip Assay Development
Target client type
Pharma, Academia, Biotech
TissUse GmbH
Busines Development Associate 
Functionality
Business Development

claire Sha China

Invest in healthcare and life science with focus on innovative technology.
Website:
www.arimedcapital.com
Partnering Objectives
Headquartner in China
Yes
AriMed Advisors Ltd
Partner 

wei sha China

Taifeng Group is a nationwide company, located in Henan province, focus on the medical industry in China. The company was established in 2005 and gradually formed a two-medicine model with both“Chinese and Western medicine research and development, manufacturing, and sales”. We developed a modern Taifeng Characteristic medicine system.
Website:
www.taifeng.co
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Henan Taifeng Medical Technology Group Co. LTD
vice president 

Rocky Shao China

HKEX list company，focusing on cardiovascular，biotechologic，ophthmalogic，oncologic，antibiotic and antivirus medicines and cardiovascular devices
Website:
www.chinageandpharm.com
Partnering Objectives
Headquartner in China
No
China Grand Pharm
Executive Director 

Dr. Leslie Sharp United States

OncoMyx Therapeutics is developing potentially best-in-class (multi-armed, IV/systemically-delivered, precision medicine) oncolytic immunotherapies based upon the myxoma virus (MYXV) platform, and we have demonstrated mechanism of action and combinatorial efficacy (tumor growth inhibition) when dosed IV with various checkpoint inhibitors in multiple animal models. Our company has the industry’s most experienced oncolytic virus (OV) development team and an experienced SAB, and CEO Steve Potts was previously an executive at Ignyta (acquired by Roche for $1.7B). OncoMyx raised a $25M series A in June 2019 to advance our lead preclinical program to IND, and among our investors are BIVF (exited OV investment ViraTx for $244M at preclinical stage in 2018) and Jonathan Lim (Ignyta CEO & current Erasca CEO). On the heels of presenting our preclinical data at SITC and announcing the appointment of Mirati CEO Chuck Baum as our new Chairperson, OncoMyx is seeking a $50M+ series B/crossover to prepare for an IPO and focus on a future transition into a clinical-stage organization. Pasted below are links to our SITC posters and some recent Fierce and BioSpace articles focused on our company.

https://www.oncomyx.com/oncomyx-announces-presentation-of-preclinical-efficacy-data-of-novel-oncolytic-immunotherapy-at-sitc-2020/
https://www.fiercebiotech.com/research/arming-rabbit-pox-virus-to-fight-cancer
https://www.biospace.com/article/oncomyx-s-oncolytic-virus-platform-shows-preclinical-efficacy-boosting-immunotherapy-potential/

Website:
https://www.oncomyx.com
Company Size (Fulltime employees)
11-50
Year of foundation
2018
Partnering Objectives
Please specify your partnering goal
Fundraising and Licensing-out
Headquartner in China
No
Biotech/Pharma Category
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 2.38MB)
OncoMyx Therapeutics
Chief Scientific Officer 
Functionality
Research and Development

Richard Shen China

A University with profound academic rrsearch
Website:
www.zju.edu.cn
Partnering Objectives
Headquartner in China
Yes
Biotech/Pharma Category
Zhejiang University
Researcher